Disaggro (Zalunfiban) for Pre-hospital Treatment of STEMI: Phase 3 Results to Be Presented at AHA 2025
CeleCor Therapeutics reposted from Dirk Sibbing on LinkedIn:
”Excited to see the news about our Phase 3 CeleBrate trial of Disaggro™ (zalunfiban) being picked up – appreciate the share Dirk Sibbing.
The full study results will be presented as part of the Late-Breaking Science Sessions at the American Heart Association Scientific Sessions (AHA 2025) in New Orleans on November 10, 2025.
Stay tuned!”
”A new drug on the horizon for pre-hospital treatment of STEMI patients
Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action
Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics
This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…
Still we are loosing too many patients pre-hospital and before we see them in the cath lab…
Results will be presented as LBCT at AHA 2025 in New Orleans”
Read the full article here.
Stay updated on the emerging with Hemostasis Today.
-
Jan 14, 2026, 16:01Renato Simonetti Presents a Pilot Project on AI-assisted Duplex Sonography for ICH
-
Jan 14, 2026, 15:47An Unusual Case from Mohammed Ameen: Unexpected Clot Unmasking Antithrombin III Deficiency
-
Jan 14, 2026, 11:38Khokon Miah Akanda Shares A major 4-Guideline Comparison on BP Management in Stroke
-
Jan 14, 2026, 11:26Pablo Albasanz-García and Colleagues on Anticancer Treatment-Induced Arterial and Venous Thrombosis
-
Jan 14, 2026, 11:16ISTH 2026: Laurent Bertoletti To Serve as Vice Theme Leader for VTE
-
Jan 14, 2026, 11:08Leni von Bonsdorff Invites You to Hear and Learn The Latest News in The Plasma Field
-
Jan 14, 2026, 05:56Arun V J on The “Whole Blood” Nostalgia Trap
-
Jan 13, 2026, 16:38Caitlin Raymond: Understanding TAMOF as a TTP-Like Process
-
Jan 13, 2026, 15:22John Amako: Childhood to Adulthood Management Approach for SCD